Mural Oncology plc
NASDAQ Global MarketTotal Valuation
Mural Oncology plc carries a market capitalization of 35.38M, placing it among publicly traded companies globally. Its enterprise value stands at -29.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 35.38M |
| Enterprise Value | -29.60M |
Share Statistics
Mural Oncology plc currently has 17.27M shares outstanding.
| Shares Outstanding | 17.27M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.18 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | -0.33 |
| P/OCF Ratio | -0.33 |
Financial Position
Mural Oncology plc maintains a current ratio of 2.87, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.87 |
| Quick Ratio | 2.71 |
| Debt / Equity | 8.80 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -91.26 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Mural Oncology plc's stock has declined approximately -44.10959% over the past 52 weeks. The 50-day moving average sits at 2.08, while the 200-day moving average is 2.37.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.10959% |
| 50-Day Moving Average | 2.08 |
| 200-Day Moving Average | 2.37 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -131.93M, while operating income came in at -135.69M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -135.69M |
| Pretax Income | -147.15M |
| Net Income | -147.15M |
| EBITDA | -131.93M |
| EBIT | -135.69M |
| Earnings Per Share (EPS) | -8.59 |
Balance Sheet
Mural Oncology plc holds 77.09M in cash and equivalents against 5.17M in total debt, resulting in a net debt position of -77.09M. Total book value stands at -240.32M, with working capital of 53.14M providing operational flexibility.
| Cash & Cash Equivalents | 77.09M |
| Total Debt | 5.17M |
| Net Debt | -77.09M |
| Equity (Book Value) | -240.32M |
| Book Value Per Share | -14.03 |
| Working Capital | 53.14M |
Cash Flow
Mural Oncology plc produced -130.01M in operating cash flow over the past twelve months. After subtracting -52,000.00 in capital expenditures, free cash flow totaled -130.06M - equivalent to -7.59 per share.
| Operating Cash Flow | -130.01M |
| Capital Expenditures | -52,000.00 |
| Free Cash Flow | -130.06M |
| FCF Per Share | -7.59 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.53 |
| FCF Yield | -307.07 |
Scores
Mural Oncology plc posts an Altman Z-Score of -7.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.35 |